Table 1 Clinicopathological characteristics and the association with HOXD11 expression in 267 PSCC patients.
Variable | PSCC cohort (N = 267), % | HOXD11 IHC staining | χ2 | p-valuea | |
|---|---|---|---|---|---|
Low expression (N = 182), % | High expression (N = 85), % | ||||
Age | 0.019 | 0.890 | |||
<55 | 143 (53.6) | 98 (36.7) | 45 (16.9) | ||
≥55 | 124 (46.4) | 84 (31.5) | 40 (15.0) | ||
pT status | 13.720 | 0.003b | |||
≤pT1c | 102 (38.2) | 78 (29.2) | 24 (9.0) | ||
pT2 | 49 (18.4) | 30 (11.2) | 19 (7.1) | ||
pT3 | 104 (39.0) | 71 (26.6) | 33 (12.4) | ||
pT4 | 12 (4.5) | 3 (1.1) | 9 (3.4) | ||
pN status | 38.695 | 0.000 | |||
N0 | 141 (52.8) | 118 (44.2) | 23 (8.6) | ||
N1 | 32 (12.0) | 21 (7.9) | 11 (4.1) | ||
N2 | 30 (11.2) | 16 (6.0) | 14 (5.2) | ||
N3 | 64 (24.0) | 27 (10.1) | 37 (13.9) | ||
Metastasis | 18.650 | 0.000b | |||
M0 | 248 (92.9) | 178 (66.7) | 70 (26.2) | ||
M1 | 19 (7.1) | 4 (1.5) | 15 (5.6) | ||
Clinical stage | 33.743 | 0.000 | |||
Stage I | 70 (26.2) | 58 (21.7) | 12 (4.5) | ||
Stage II | 70 (26.2) | 57 (21.3) | 13 (4.9) | ||
Stage III | 55 (20.6) | 36 (13.5) | 19 (7.1) | ||
Stage IV | 72 (27.0) | 31 (11.6) | 41 (15.4) | ||
Histology | 9.006 | 0.011 | |||
G1 | 129 (48.3) | 99 (37.1) | 30 (11.2) | ||
G2 | 95 (35.6) | 59 (22.1) | 36 (13.5) | ||
G3 | 43 (16.1) | 24 (9.0) | 19 (7.1) | ||
ENE | 23.887 | 0.000 | |||
No | 218 (81.6) | 163 (61.0) | 55 (20.6) | ||
Yes | 49 (18.4) | 19 (7.1) | 30 (11.2) | ||
PLNMd | 4.298 | 0.038 | |||
No | 23 (62.2) | 20 (54.1) | 3 (8.1) | ||
Yes | 14 (37.8) | 7 (18.9) | 7 (18.9) | ||